Skip to main content
. Author manuscript; available in PMC: 2023 Jan 25.
Published in final edited form as: Nat Med. 2022 Apr 11;28(5):1022–1030. doi: 10.1038/s41591-022-01762-x

Fig. 4 ∣. Longitudinal serum VRC07 concentration and tier 1 and tier 2 ADA from immediately before IM injection of AAV8-VRC07 to 80–156 weeks after IM injection of 5 × 1010, 5 × 1011 and 2.5 × 1012 vg kg−1.

Fig. 4 ∣

Participants without tier 1 and tier 2 ADA are shown in the left column; participants with tier 1 and tier 2 ADA are shown in the right column. Serum VRC07 concentrations for different participants are as shown by colored lined as indicated in the figure legend. Tier 1 ADA is as indicated by black lines, with tier 2 ADA as indicated by solid colored bars over the time at which they were identified. No tier 3 ADA was identified for any participants. For VRC07 concentration data, all data points represent the results of a single assay performed in triplicate. Tier 2 and tier 3 ADA responses represent the average of a single assay done in quadruplicate.